• FDA Again Dings Heron's Opioid Alternative Over “Nonclinical Issues”

    15 days ago - By Xconomy

    Heron Therapeutics revealed Monday that its investigational non-opioid drug for treating postoperative pain has again been rejected by the FDA. The San Diego company's HTX-011 is an extended-release solution of bupivacaine, a local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug. Heron positioned it as a pain management option that could contribute to a needed reduction in the use of opioid-based medications, which have a high potential for addiction. According to the company , the FDA's complete response letter received Friday asked for more information about four...
    Read more ...

     

  • Heron's wings clipped again with another FDA rejection for opioid alternative

    Heron's wings clipped again with another FDA rejection for opioid alternative

    15 days ago - By Fierce Biotech

    Heron's wings clipped again with another FDA rejection for opioid alternative badams
    Mon, 06/29/2020 - 09:13
    Read more ...